Mangoceuticals

Key facts

Headquarters

DALLAS, Texas, United States

Employees

14

Industries

Biotechnology, Dietary Supplements, Health Care

Status

Public (MGRX)

Website

www.mangoceuticals.com

LinkedIn

Company page

Recent activity at Mangoceuticals

• Nov 06, 2026: SEC 8-K (8.01): The Company has announced its combined 2025 and 2026 Annual Meeting of Shareholders, scheduled for December 30, 2026, at its offices located at 17130 N. Dallas Parkway, Suite 240, Dallas, Texas. Shareholders of record as of November 12, 2026, will have voting rights and be notified of the meeting. The Company is allowing shareholder proposals to be submitted by November 16, 2026, and any proposals after this deadline will not be recognized. This event is significant as it involves planned governance matters and shareholder participation, critical for corporate decision-making.
• Oct 08, 2026: SEC 8-K (1.01): On October 8, 2026, Mangoceuticals, Inc. entered into a securities purchase agreement with certain investors to issue and sell 657,000 shares of its common stock and common warrants to purchase up to an additional 657,000 shares. The offering included up to 788,400 shares of common stock issuable upon the exercise of the warrants. This registered direct offering represents a strategic fundraising effort, aiming to enhance the company's capital structure and support future business initiatives. The transaction conditions include the combined sale of shares and warrants, reflecting a proactive approach to raising capital in the current market environment.
• Sep 30, 2026: SEC 8-K (1.01): On September 30, 2026, MangoRx IP Holdings, LLC, a wholly-owned subsidiary of Mangoceuticals, Inc., entered into Subscription Agreements with two accredited investors. One investor agreed to purchase a 12.5% stake in MangoRx IP for a total of $1,250,000, with an initial payment of $500,000 due immediately and a subsequent payment of $750,000 to be made later. This transaction is significant as it involves the patent portfolio behind the Company's antiviral technology, MGX-0024, indicating a strategic move to finance the growth and development of this technology. The partnership could enhance Mangoceuticals' position in the pharmaceutical sector.
• Sep 30, 2026: Mangoceuticals Secures $1.25 Million from Investors
• Aug 19, 2026: SEC 8-K (1.02): On August 19, 2026, Mangoceuticals, Inc. ('MGRX') and Nuclea Energy Inc. mutually agreed to terminate their Business Combination Agreement ('BCA') dated July 29, 2026. This agreement aimed to facilitate a strategic business combination transaction between MGRX and Nuclea, which would have included PIPE financing as a closing condition. The termination follows the stipulations set forth in Section 12.1(a) of the BCA and reflects the parties' decision not to pursue the transaction further, impacting potential synergies and business growth strategies initially anticipated from the merger.
• Aug 04, 2026: SEC 8-K (8.01): On August 4, 2026, Mangoceuticals, Inc. received a notice from Nasdaq granting it an additional 180-day compliance period to regain compliance with the minimum bid price requirement after addressing a prior deficiency regarding its stock closing below $1.00 per share. The new deadline for compliance is February 1, 2027, during which the Company may implement a reverse stock split as a potential remedy. This filing also includes an announcement about a business combination agreement with Nuclea Energy Inc., highlighting the Company's strategic efforts to enhance its market position while actively monitoring stock performance to resolve the listing deficiency.
• Jul 31, 2026: Mangoceuticals to merge with Nuclea Energy
• Jul 30, 2026: SEC 8-K (5.02): On July 28, 2026, the Company announced the departure of Chief Executive Officer Jacob D. Cohen, whose termination is classified as a Good Reason/without Cause. Following this event, Mr. Cohen will transition to the role of President in an independent consulting capacity. Additionally, post-approval of the BCA transactions, new directors and executive officers will be appointed as determined by Principal Nuclea Shareholders, leading to resignations of existing officers not reappointed. Furthermore, the Board authorized the issuance of 400,000 fully vested shares of common stock to Directors and the CFO, conditioned on compliance with regulations and internal plan provisions.
• Jul 02, 2026: SEC 8-K (1.01): On June 29, 2026, Mangoceuticals, Inc. entered into a Subscription Agreement with an accredited investor for the purchase of 850,000 shares of restricted common stock at a price of $0.32 per share, totaling $272,000. The Subscription Agreement includes customary representations and warranties, along with piggyback registration rights for one year. The securities issued under this agreement are unregistered and are exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as the offering did not involve a public offering, and the investor has access to pertinent information. The shares are subject to transfer restrictions, emphasizing their unregistered status and the need for compliance with applicable securities laws.
• Mar 17, 2026: SEC 8-K (5.02): On March 16, 2026, Mangoceuticals, Inc. approved an option repricing for its Chief Executive Officer and Chairman, Jacob Cohen. The repricing involved reducing the exercise price of outstanding stock options held by Mr. Cohen to $0.45 per share, which was above the common stock's closing price on that day. This decision followed recommendations from the Compensation Committee and was approved by the disinterested members of the Board after carefully reviewing various factors. The options affected included 50,000 shares granted on August 31, 2022, 83,333 shares granted on December 28, 2023, and 2,000,000 shares granted on September 9, 2025, each having their original exercise prices reduced significantly. Mr. Cohen recused himself from the approval process due to his interest in the options being repriced.

Mangoceuticals funding history

Leadership

• Zvonimir, Director of Operations
• Jonathan Arango, Executive Officer, Director
• Jacob Cohen, Executive Officer, Director
• Amanda Hammer, Chief Operating Officer

Verified email and direct lines for Mangoceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Mangoceuticals in the news

• Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. - Yahoo Finance (Mar 17, 2026)
• Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor - TMX Newsfile (Jul 30, 2026)
• An 8% annual dividend rate is set for Mangoceuticals' planned tokenized stock, payable if declared. - Stock Titan (Nov 12, 2026)
• Mangoceuticals Secures $2.5 Million Strategic Investment in - GlobeNewswire (Oct 01, 2026)
• Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close - GlobeNewswire (Oct 09, 2026)
• Mangoceuticals’ Patented MGX-0024 Achieves Zero - GlobeNewswire (Feb 23, 2026)

Companies similar to Mangoceuticals

• AuNutra Industries · Biotechnology, Dietary Supplements, Health Care, Nutrition
• Bio Cell Tech FZCO · Biotechnology, Dietary Supplements, Health Care, Nutrition
• The Func. Lab · Biotechnology, Dietary Supplements, Health Care, Nutrition
• Restart Life Sciences · Biotechnology, Dietary Supplements, Health Care, Nutrition
• KÄÄPÄ Biotech · Biotechnology, Dietary Supplements, Health Care, Nutrition

About Mangoceuticals: questions and answers

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy